High-Dose Cyclophosphamide for Steroid Refractory GVHD
Completed · Phase 2
Conditions studied: Graft Versus Host Disease
In brief
RATIONALE: High-dose cyclophosphamide may be an effective treatment for acute graft-versus-host disease that did not respond to steroid therapy. PURPOSE: This phase II trial is studying the side effects, best dose, and how well high-dose cyclophosphamide works in treating patients with acute graft-versus-host disease that did not respond to steroid therapy.
Key facts
- Study ID
- NCT00492921
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 12
- Starts
- 2007-05-01
- Expected to finish
- 2013-01-01
- Last updated by the study team
- 2018-09-14
Who can join
Age: any, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.